MedTrace Logo

Natriuretic Peptides as a Prognostic and Risk Stratification Tool in Assessment of Valvular Heart Disease

NCT05439369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-06-30

No results posted yet for this study

Summary

NPs can be used To detect subset of asymptomatic with subtle LV dysfunction for further evaluation and earlier referral for intervention and its correlation with echocardiographic finding.

Conditions

  • Valvular Heart Disease Stenosis and Regurgitation

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohamed Aly Abdelhafez, Lecturer · Assiut University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439369 on ClinicalTrials.gov